Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalinfixed paraffin-embedded tissue of nonsmall cell lung cancer

Detection of epidermal growth factor receptor (EGFR) mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients.